Moors & Cabot Inc. Acquires 3,498 Shares of Amgen Inc. $AMGN

Moors & Cabot Inc. raised its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 23.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,382 shares of the medical research company’s stock after acquiring an additional 3,498 shares during the period. Moors & Cabot Inc.’s holdings in Amgen were worth $7,748,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. MW Advisory LLC acquired a new stake in shares of Amgen in the 2nd quarter worth about $1,054,000. Baird Financial Group Inc. increased its holdings in shares of Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after acquiring an additional 5,496 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Amgen by 105.8% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock valued at $5,696,000 after purchasing an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC bought a new stake in Amgen in the 2nd quarter valued at about $3,329,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $465.67 on Monday. The stock has a market cap of $251.89 billion, a P/E ratio of 27.01, a P/E/G ratio of 3.24 and a beta of 0.43. The firm’s 50-day simple moving average is $425.31 and its 200 day simple moving average is $381.17. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. Amgen’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.64 EPS. Equities analysts expect that Amgen Inc. will post 23.37 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is currently 58.47%.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Citigroup raised their price target on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. HSBC cut Amgen from a “buy” rating to a “hold” rating and cut their price target for the company from $445.00 to $425.00 in a report on Thursday, September 10th. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. Finally, Leerink Partners boosted their price objective on Amgen from $395.00 to $464.00 and gave the stock a “market perform” rating in a research report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $424.66.

View Our Latest Research Report on AMGN

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.